Ondansetron, Alcohol Use, and Alcohol-Related Symptoms In HIV+ Persons
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
The proposed randomized clinical trial will investigate a novel pharmacotherapy for hazardous
drinking, HIV-infected men and women, using the serotonin receptor (5-HT3) antagonist
ondansetron. The investigators predict that participants who are treated with active doses of
ondansetron will reduce their drinking more and show better HIV treatment participation and
progress compared to participants who are treated with placebo. This study will provide
important new safety and efficacy results on drinking and HIV outcomes following alcohol
pharmacotherapy in HIV-infected persons.
Phase:
Phase 2
Details
Lead Sponsor:
Johns Hopkins University
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)